SCHEMBL2863497

SCHEMBL2863497

CC(C)C1=CC(C)(C)c2cc3c(cc21)Cc1ccccc1-3

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.44
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CYP17A1 P05093 1/20 0.36
SRD5A2 P31213 1/20 0.36
MAOA P21397 2/20 0.35
ADRA2A P08913 1/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2863494 0.94 PGR (0.47) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2865826 0.82 PGR (0.32) PGR
SCHEMBL2863031 0.80 PGR (0.57) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2870970 0.77 PGR (0.44) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL2863029 0.74 PGR (0.61) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL30912172 0.73 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL5016641 0.73 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL18582934 0.73 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL5058433 0.73 SMN1; SMN2 (0.64) PGRALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL8161302 0.71 CYP17A1 (0.50) PGRALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834204-B2 Fluorene derivative, transition metal compound, catalyst for olefin polymerization, and process for producing olefin polymer MITSUI CHEMICALS, INC. (JP) 2010-11-16 US disclosed
US-20090253876-A1 Fluorene Derivative, Transition Metal Compound, Catalyst for Olefin Polymerization, and Process for Producing Olefin Polymer MITSUI CHEMICALS, INC. 2009-10-08 US disclosed
EP-1900715-A1 FLUORENE DERIVATIVE, TRANSITION METAL COMPOUND, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER Mitsui Chemicals, Inc. (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253876-A1 Fluorene Derivative, Transition Metal Compound, Catalyst for Olefin Polymerization, and Process for Producing Olefin Polymer AFF4, OR10J3, DRD1 PGR 2102/4885ALDH1A1 3472/4885MAPT 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.